Human leukocyte antigen class I alleles can predict response to pegylated interferon/ribavirin therapy in chronic hepatitis C Egyptian patients.

doi:013162/AIM.004

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Human leukocyte antigen class I alleles can predict response to pegylated interferon/ribavirin therapy in chronic hepatitis C Egyptian patients.

Archives of Iranian medicine - 1 Feb 2013

Farag Raghda E, Arafa Mona M, El-Etreby Shahira, Saudy Niveen S, Eldeek Basem S, El-Alfy Hatem A, Goda Inas F, Ali Rabab M

Abstract excerpt

BACKGROUND: Racial differences and broad spectrum response to anti-hepatitis C (anti-HCV) therapy suggest a possible role for host genetic diversity in treatment outcomes. We aim to determine the association and predictive value of certain human leukocyte antigen (HLA) class I alleles with either susceptibility to viral clearance or persistence following pegylated interferon (Peg-IFN) plus ribavirin therapy in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination
Share to Egypt

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, MHC Class I

Share to Hepatitis C, Chronic

Share to Interferons

Share to Ribavirin

Share to Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 23360626
DOI: 013162/AIM.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.